Pharmacy

The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted Sept. 23 in favor of approving Grail’s Galleri multi-cancer early-detection blood test. The vote marks the first time a test of this kind has reached this…

An FDA advisory panel will meet Sept. 23 to review GRAIL’s Galleri test, a blood-based screening tool for multiple cancer types that would be the first FDA-authorized multi-cancer early detection device if approved, according to the agency’s executive summary released…

An investigational immunotherapy was found to almost double median overall survival in patients with previously treated squamous non-small cell lung cancer, according to new trial data. Gotistobart, developed by BioNTech and OncoC4, showed a median overall survival of 18.5 months,…

Among 31 cancer centers, 100% said they were experiencing a shortage of at least one anti-cancer drug, according to data published Sept. 10 by the National Comprehensive Cancer Network. The data summarizes August survey responses from pharmacy directors and other…

The FDA has granted accelerated approval to Etcamah (camizestrant), marking the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA before imaging tests show disease progression. Etcamah is used with…

The U.S. shortage of the chemotherapy drug ifosfamide has reached a “critical” stage, according to an Aug. 25 news release from the American Society of Clinical Oncology.  To address the shortage, the FDA is allowing overseas manufacturers to temporarily import…

The FDA has approved Rasonque (daraxonrasib) for adults with advanced pancreatic cancer that has stopped responding to earlier treatment, or for patients too sick for standard combination chemotherapy. The drug improved median overall survival to 13.2 months compared with just…

The FDA has approved new first-line treatment options for adults with certain HER2-positive gastric, gastroesophageal junction and esophageal cancers. The agency approved Ziihera in combination with Tevimbra and fluoropyrimidine- and platinum-containing chemotherapy for adults with HER2-positive, unresectable, locally advanced or…

Tampa, Fla.-based Moffitt Cancer Center has launched a radiopharmaceutical program at its Land O’ Lakes, Fla.-based research facility and medical campus, Speros. The program will focus on radiopharmaceutical research, development, clinical translation and manufacturing. The program will be led by…

Mark Cuban Cost Plus Drug Co. has partnered with RxSaveCard and nonprofit Golden Thread to streamline sourcing and reduce costs of pediatric cancer clinical trial medications.  Once enrolled in a study, patients will sign up for RxSaveCard and receive trial…